drugset / Trial / NCT01625897

A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia

NCT01625897

Phase 2/3 Completed 125 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.

Timeline

Start
2012-05
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 9 mg Oral
Comparator Risperidone Other / unclassified 2 mg Oral
Comparator Risperidone Other / unclassified 12 mg Oral

Indications